Pre-clinical In Vitro and In Vivo Characterization of a Novel EGFR Sparing ErbB2 Inhibitor with Activity Against Oncogenic ErbB2 Mutations. (October 2022) - Chicarelli, M.J.; Bouhana, K.; Cable, L.; Crow, M.; Fell, B.; Fischer, J.; Fulton, J.; Guarnieri, A.; Jalluri, R.; Robinson, J.; Sullivan, F.; Winski, S.; et al.